GlaxoSmithKline: An update on SFO investigation
GlaxoSmithKline isn’t out of the weeds yet. The pharmaceutical company this week said the U.K. Serious Fraud Office has requested new information relating to an ongoing investigation, this time concerning third-party advisers engaged by the company.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
Blog
SFO faces criticism for closing Rolls-Royce, GSK cases
The U.K. Serious Fraud Office closed two long-running bribery and corruption cases against Rolls-Royce and GlaxoSmithKline—a decision that casts further doubt around the effectiveness of the SFO’s investigatory powers and makes companies question the purpose of entering a deferred prosecution agreement at all.
-
Blog
Why is the U.S. government investigating GlaxoSmithKline now?
GlaxoSmithKline recently said U.S. enforcement agencies asked for information about third-party advisers the company hired in China during a corruption investigation in the country. The Man From FCPA asks, why now?
-
ArticleLong-running corruption scandal adds €25.8M fine to billions already paid globally
The Netherlands Public Prosecution Office has fined a company linked to a U.S.-sanctioned Israeli businessman €25.8 million ($29.9 million) for bribing officials in the Congo. The case began in 2018 and relates to bribes paid in 2010-2011, demonstrating the slow and complex process often involved in such investigations.